A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors

Amgen Inc0 个研究点目标入组 36 人开始时间: 2015年1月22日最近更新: 2015年1月26日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Amgen Inc
入组人数: 36

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•All parents or legal guardians must provide voluntary, signed-written informed consent before any study-specific procedure is conducted. In addition to providing written informed consent, the assent of the child (if applicable) must also be obtained in accordance with the institutional review board (IRB)/independent ethics committee before
•any study-specific procedure is conducted.
•1 to < 18 years of age
•Histologically or cytologically confirmed solid tumor that has recurred after standard therapy, or for which there is no standard therapy. Subjects with brainstem glioma DO NOT need histologic proof of the diagnosis.
•Central nervous system (CNS) tumors (primary or metastatic) are allowed.
•Subjects who have received prior radiotherapy for CNS metastases must have a minimum of 4 weeks elapsed since last dose of radiotherapy and be considered medically stable and must be on a stable dose of corticosteroids for a minimum of 2 weeks prior to participation in the study.
•Paraffin-embedded tumor tissue from primary tumor or metastasis for determination of epidermal growth factor receptor (EGFr) expression and biomarker testing (not required for brainstem gliomas, if not available)
•Presence of measurable or non-measurable disease
•Life expectancy of = 12 weeks
•Performance status: Karnofsky = 60% for 12 to < 18 years of age (Appendix M); Lansky play scale = 60% for children 1 to < 12 years of age (Appendix N)
•Adequate hematologic function, as follows:
•- Absolute neutrophil count (ANC) = 1.5 x 109/L
•- Platelet count = 75 x 109/L
•- Hemoglobin = 9 g/dL
•Adequate renal function as follows:
•- Serum creatinine = 1.5 x upper limit of normal (ULN) for age
•Adequate hepatic function, as follows:
•- Aspartate aminotransferase (AST) = 3 x ULN (= 5 X ULN if liver metastases)
•- Alanine aminotransferase (ALT) = 3 x ULN (= 5 X ULN if liver metastases)
•- Total bilirubin = 1.5 X ULN
•Magnesium = lower limit of normal
•Adequate pulmonary function, as follows:
•- Resting O2 saturation on room air = 92% by pulse oximetry
•All previous therapy-related toxicities must have resolved or returned to baseline
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 24
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Diagnosis of leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, or other hematologic malignancy
•Any prior allogeneic transplant
•Prior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to enrollment
•Substantial radiotherapy to the bone marrow within 6 weeks prior to enrollment (or within 6 months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least 59% of the pelvis was received; within 2 weeks prior to enrollment if local palliative radiotherapy was received)
•Prior use of any monoclonal antibodies directly targeting the EGFr. Subjects who have received prior tyrosine kinase inhibitors such as gefitinib (Iressa) or erlotinib (Tarceva) are eligible.
•Immunotherapy, radiotherapy, or chemotherapy = 2 weeks prior to enrollment (= 6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and = 6 weeks from prior antibody therapy)
•Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except for pain control), or any other investigational drug while on this study
•Prior seizures < 3 months prior to enrollment. Subjects with a history of seizure disorders = 3 months prior to enrollment must be seizure free and on stable anticonvulsant medication(s) for = 3 months prior to enrollment.
•Presence of a serious uncontrolled medical disorder
•Dementia, altered mental status, or any other medical condition or disorder that would prohibit the understanding or rendering of assent (if applicable), or ability to comply with study procedures
•Major surgery = 28 days prior to enrollment
•Known or suspected history of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)
•Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as = CTC grade 2 [CTCAE version 3.0])
•Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity
•Females of childbearing potential not using adequate contraception precautions for the duration of the study treatment and for 2 months after the last administration of investigational product
•Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product
•Received investigational therapy or procedure = 30 days prior to enrollment

研究者

发起方

Amgen Inc

相似试验

已完成

1 期

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid TumorsAdvanced Solid Tumors

JPRN-jRCT2080223391AstraZeneca6

已完成

不适用

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects with Glioblastoma MultiformeGrade 4 Brain tumor10029211Glioblastoma

NL-OMON41552AbbVie B.V.10

尚未招募

1 期

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Cavrotolimod in Subjects with Chronic Hepatitis B InfectioChronic Hepatitis B InfectionInfection - Other infectious diseases

ACTRN12624000808549Bluejay Therapeutics, Inc40

尚未招募

1 期

ACTRN12624000809538Bluejay Therapeutics, Inc80

未知

1 期

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients with Advanced or Refractory Solid Tumors or Lymphoma

JPRN-jRCT2080223021Janssen Pharmaceutical K.K.33